MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Phase 2 Unknown 55 enrolled Matrix Biomed, Inc. Prostate Oncology Specialists, Inc. · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open label trial to assess the efficacy of MBM-02 (Tempol) as a treatment for patients diagnosed with prostate cancer in biochemical recurrence.

Timeline

Start: 2021-05-30
Primary completion: 2022-09
Completion: 2023-02

Publications

Background Thomas R, Sharifi N. SOD mimetics: a novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer. Mol Cancer Ther. 2012 Jan;11(1):87-97. doi: 10.1158/1535-7163.MCT-11-0540. Epub 2011 Dec 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tempol	Small molecule	600 mg	—
Subject	Tempol	Small molecule	1000 mg	—
Subject	Tempol	Small molecule	1200 mg	—
Subject	Tempol	Small molecule	1600 mg	—

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications